Inspire Medical (INSP) Takes 32% Nosedive on Dismal Earnings, Outlook

We recently published 10 Big Names Bleed Double Digits. Inspire Medical Systems, Inc. (NYSE:INSP) is one of the worst-performing stocks on Tuesday.

Inspire Medical nosedived by 32.35 percent on Tuesday to end at $87.91 apiece as investors unloaded portfolios following a disappointing earnings performance in the second quarter of the year, coupled with a lower growth outlook for the full year.

This followed the company’s swing to a $3.59 million net loss in the second quarter of the year, reversing a $9.8 million net income in the same period last year.

Revenues, however, jumped by 10.7 percent to $217 million from $195.88 million in the same comparable period.

In the first half, Inspire Medical Systems, Inc. (NYSE:INSP) said it widened its net loss by 183 percent to $600 million from $212 million, while revenues grew by 16 percent to $418 million from $360 million.

Commenting on the company’s performance, Inspire Medical Systems, Inc. (NYSE:INSP) Chairman and CEO Tim Herbert believed that operational headwinds were just temporary and that actions are underway to address them.

For full-year 2025, the company expects revenues to now settle between $900 million and $910 million, lower than the $940 million to $955 million expected previously.

While we acknowledge the potential of INSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.